Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OrbusNeich

Explore full profile

A global pioneer in the development of life-changing vascular solutions

Sha Tin District, Hong KongFounded 2005Health Tech & Medtech
Valuation $1–2.5B Last recorded · 2022
Revenue $100–500M Latest reported FY
Headcount 100–500 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for OrbusNeich and the history behind them.

About OrbusNeich

OrbusNeich is a global leader in the design, development, manufacturing, and marketing of innovative medical devices aimed at treating vascular diseases. The company primarily serves healthcare providers, including hospitals and specialized medical centers, that focus on cardiovascular treatments. Operating in the medical device industry, OrbusNeich's core products include advanced stents and balloon catheters, which are essential for procedures like angioplasty and percutaneous coronary intervention (PCI).

Read full description

The business model revolves around the continuous innovation and improvement of its product line to meet the evolving needs of the cardiovascular healthcare sector. Revenue is generated through the direct sale of these medical devices to healthcare institutions worldwide. OrbusNeich has a strong presence in key markets, including Asia, Europe, and the Americas, and has received regulatory approvals in multiple countries, enhancing its market reach and credibility.

Key products like the COMBO Dual Therapy Stent and Sapphire II PRO balloons are designed to improve patient outcomes by reducing complications such as stent thrombosis. The company's commitment to research and development ensures that it remains at the forefront of medical technology, offering solutions that address both current and future healthcare challenges.

Source: Dealroom company data

At a glance

Founded
2005
Headquarters
Sha Tin District, Hong Kong
Sector
Health Tech & Medtech
Power Law
Thoroughbred$100M+ revenue

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Series B and later1 investor entered at this stage

  • Hangzhou Fuyang Industrial Fund Investment Management
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
20 countries with
team presence
🇳🇱 Netherlands17.6%
🇭🇰 Hong Kong16%
🇲🇾 Malaysia13.6%
🇩🇪 Germany12.8%
🇨🇳 China8%
Top 5 of 20 shown
Web traffic by country
10K monthly visits
across markets
🇺🇸 United States31%
🇻🇳 Vietnam17%
🇭🇰 Hong Kong13%
🇨🇭 Switzerland13%
🇮🇩 Indonesia7%
Top 5 markets shown

Patents

Estimated portfolio value
$26M

90 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OrbusNeich on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OrbusNeich on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.